Mechanistic Understanding of Disease Biomarkers through Metabolomics
Ed Karoly, Ph.D.,
Project Director
Metabolon
|
|
Abstract: Of all the “omics” disciplines metabolomics, or global biochemical profiling, is potentially the most powerful with respect to understanding disease mechanisms. Providing the complete biochemical profile of a cell or tissue under a specific set of conditions, metabolomics focuses on small molecule metabolites as well as lipids, hormones, amino acids, nucleosides, cofactors, carbohydrates and others.
Comparing metabolomic differences between healthy individuals and those with diseases helps identify and unravel disease mechanisms through disease-mediated biochemical changes. Most of these significant alterations in the metabolome occur very soon after disease onset and are linked to the cellular changes representing the disease phenotype. These changes not only point to disease mechanisms but potential biochemical markers for diagnostic tests as well as targets for future intervention.
This session will explore the basic concepts of metabolomics technology and how the technology has recently been applied to understanding the mechanism of several major diseases, including prostate cancer.
Presenter Biography: Edward Karoly received his Ph.D. in Toxicology from North Carolina State University where he studied cloning and expression of FMO isoforms in the mouse. Following this, he was a post doctorial scientist with the U.S. EPA where he gained extensive experience in microarray data analysis and interpretation. He is currently a project leader at Metabolon Inc. (RTP, NC) where he manages metabolomics projects which provide insight into complex biochemical processes such as drug action, disease, toxicology and bioprocess optimization.
Online Presentation: http://lifescience.planetconnect.com/ppt/LSPrinceton/tuesday/ED_KAROLY.ppt
|
